Bispecific Antibodies: Strategies Available to Optimize Their Safe Delivery in Patients with Multiple Myeloma
Bispecific antibodies (BsAbs) have emerged as an important new class drugs for the treatment of multiple myeloma (MM) over the last few years. Currently, BsAbs are only licensed for use as monotherapy in patients with relapsed/refractory MM who have had at least three prior lines of treatment and ar...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
MDPI AG
2026-01-01
|
| Schriftenreihe: | Antibodies |
| Schlagworte: | |
| Online-Zugang: | https://www.mdpi.com/2073-4468/15/1/5 |
| Tags: |
Keine Tags, Fügen Sie das erste Tag hinzu!
|